Developing a ranking system for the most favorable targets, with most chance of efficacy but least predicted “on target, off tumor” toxicity, we found BCMA and several other clinically-investigated targets as top-ranked antigens, an encouraging validation of our approach. Here, TNFRSF17 is linked to neoplasm.